relypsa
A Vifor Pharma Group Company

You are cordially invited

to attend a Speaker Program on VELTASSA® (patiromer) for Oral Suspension.

Speaker Program Invitation

Mukesh Sharma, MD, MS, FACP, FASDIN

Nephrologist
Arkansas Renal Group, P.A.
Hot Springs, AR

Arthur's Prime Steakhouse

16100 Chenal Parkway
Little Rock, AR 72223
501-821-1838

Monday, April 22, 2019, at 6:00 PM

Please RSVP by April 17, 2019 to
Deborah Wilkins at dwilkins@relypsa.com
or via phone at 479-462-5663

Potassium Rising – Addressing a Recurring Threat in Patients

INDICATION AND USE:

VELTASSA is indicated for the treatment of hyperkalemia.
Limitation of use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

IMPORTANT SAFETY INFORMATION:

Contraindication: Patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

Adverse Reactions: The most common adverse reactions (incidence ≥2%) are constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence. Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.

Please see accompanying full Prescribing Information

IMPORTANT NOTE:

HCPs are encouraged but not required to bring their National Provider Identifier (NPI) and/or a State License Number (SLN) to the program. This information will only be used for reporting purposes. You may look up your NPI and SLN at: https://npidb.org/npi-lookup/.

Relypsa adheres to the PhRMA Code and complies with all federal and state reporting requirements. As required, meals and beverages provided and accepted by HCPs may be subject to reporting. If you are a HCP from certain states (such as Minnesota or Vermont), you may be subject to additional restrictions for receipt of meals. If you are a federal government employee, you may not be permitted to partake of a meal. Relypsa will neither recommend, endorse, nor support the submission of this program for CME credits.

If you wish to stop receiving communications from Relypsa regarding speaker programs, please send an email with UNSUBSCRIBE in the subject or body to: VeltassaPrograms@insyght.com.

Scan QR code to download the new k+nowledge hub app and access additional information on this program! Access ID: 915923
Speaker Program ID: 13645